RXRX CIK: 1601830

Recursion Pharmaceuticals, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−159
FY22:
−83.5
FY23:
−288
FY24:
−359
FY25:
−372
Change from FY21 to FY25
millions USD
FY21:
−272
FY22:
193
FY23:
−10.2
FY24:
260
FY25:
−16.9
Change from FY21 to FY25
millions USD
FY21:
459
FY22:
154
FY23:
140
FY24:
304
FY25:
522
millions USD
FY21:
28.2
FY22:
264
FY23:
−158
FY24:
202
FY25:
151
(positive)
Change from FY21 to FY25
millions USD
FY21:
−198
FY22:
−121
FY23:
−300
FY24:
−373
FY25:
−378

All amounts in millions USD Data source:SEC EDGAR